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Pharmacological treatment and prevention of cerebral small vessel disease: a
review of potential interventions
Philip M. Bath1* and Joanna M. Wardlaw2
Small vessel disease encompasses lacunar stroke, white matter
hyperintensities, lacunes and microbleeds. It causes a quarter
of all ischemic strokes, is the commonest cause of vascular
dementia, and the cause is incompletely understood. Vascular
prophylaxis, as appropriate for large artery disease and car-
dioembolism, includes antithrombotics, and blood pressure
and lipid lowering; however, these strategies may not be
effective for small vessel disease, or are already used routinely
so precluding further detailed study. Further, intensive anti-
platelet therapy is known to be hazardous in small vessel
disease through enhanced bleeding. Whether acetylcholinest-
erase inhibitors, which delay the progression of Alzheimer’s
dementia, are relevant in small vessel disease remains unclear.
Potential prophylactic and treatment strategies might be those
that target brain microvascular endothelium and the blood
brain barrier, microvascular function and neuroinflammation.
Potential interventions include endothelin antagonists, neuro-
trophins, nitric oxide donors and phosphodiesterase 5
inhibitors, peroxisome proliferator-activated receptor-gamma
agonists, and prostacyclin mimics and phosphodiesterase 3
inhibitors. Several drugs that have relevant properties are
licensed for other disorders, offering the possibility of drug
repurposing. Others are in development. Since influencing
multiple targets may be most effective, using multiple agents
and/or those that have multiple effects may be preferable. We
focus on potential small vessel disease mechanistic targets,
summarize drugs that have relevant actions, and review data
available from randomized trials on their actions and on the
available evidence for their use in lacunar stroke.
Key words: antithrombotics, blood brain barrier, blood pressure lowering,
cyclic nucleotide inhibitors, nitric oxide, prostacyclin
Introduction
Small vessel disease (SVD) causes a quarter of all ischemic strokes
(lacunar stroke) (1) and is the commonest cause of vascular
dementia. The cause of SVD, which also includes white matter
hyperintensities (WMH), lacunes andmicrobleeds (2,3), is, as yet,
incompletely understood. Although conventional vascular pro-
phylaxis, such as intensive antiplatelet therapy, may not be effec-
tive for small vessel disease, there are many other therapeutic
targets (4), and drugs to test in clinical trials. Here we review all
available drugs with actions that are relevant to suspected mecha-
nisms of intrinsic SVD and all available evidence on use of any of
these drugs to prevent lacunar stroke and SVD.
Background
A quarter of ischemic strokes (≈30 000 per year in the UK) are
lacunar or small subcortical in type (Fig. 1) (1). These usually
cause mild to moderate neurological deficit with low early mor-
tality, but can be physically disabling and have a high long-term
risk of recurrence and cognitive impairment (5,6). Lacunar stroke
is associated with subclinical abnormalities that contribute to the
burden of brain damage causing insidious physical and cognitive
deficits and vascular dementia (7), and increasing the societal
impact beyond that expected from the small size of the infarct
alone (3). These abnormalities are easily detected on magnetic
resonance imaging (MRI) brain imaging, and include lacunar or
small subcortical infarction, lacunes, white matter hyperintensi-
ties (WMH) (8) and microbleeds (9). Although they may present
after a clinically-overt event, most lacunes (10), subcortical grey
or white matter hyperintensities and microbleeds develop
‘silently’. When numerous, all three are associated with cognitive
impairment, doubling the risk of dementia and trebling the risk of
stroke (11,12). Together with lacunar stroke, these features are
collectively known as cerebral small vessel disease (SVD; Fig. 1) (2).
Small haemorrhages can also present with lacunar stroke (13);
and an as yet unknown proportion of large haemorrhages are also
now recognized to have SVD as the major underlying pathology
(Fig. 1).
Properties of pharmacological agents needed
for SVD
The slow development of SVD and its chronic nature suggest that
any intervention for its prevention or treatment will need to be
given long-term. The high prevalence of SVD (e.g. a quarter of all
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ischemic strokes; 45% of all age-related dementias;WMH present
in 17+% at age 70 + (11,14)) suggests that any long-term inter-
vention will need to come at modest financial cost to both indi-
viduals and society. Extrapolating from these two observations,
any effective intervention will have to be administered as an oral,
transdermal or nasal preparation, or possibly via a long-acting
injectable. Since the target population will include many older
people who may be on multiple drugs for other indications (e.g.
vascular prophylaxis, arthritis, gastro-oesophageal reflux, laxa-
tives), an intervention with limited drug interactions and once (or
twice) daily administration will be preferable. The growing
number of very elderly people makes it imperative that patients
aged over 85 are included in future trials – few have been included
in stroke prevention trials to date.
Clinical targets include reducing first or recurrent stroke, and
preventing cognitive decline and physical disabilities such as
impaired balance or gait, or neuropsychological symptoms (15).
Imaging targets include preventing the development of new
lacunes, microbleeds and brain atrophy, and delaying the wors-
ening of WMH. It is important to use accurate lesion quantifica-
tion methods and in particular to avoid confounding of imaging
measurements by, for example, including a recurrent cortical or
large subcortical infarct inWMH volume which would artificially
inflate the apparent WMH burden. Additional targets for detect-
ing reduced brain damage include checking if treatments reduce
global brain (16) or focal regional cortical or brainstem atrophy
(17,18) that occur secondary to WMH and incident lacunar isch-
emic strokes respectively. Importantly, the effectiveness of an
agent in the acute situation does not mean that it will be effective
in long-term prevention; adaptation may be a problem with some
agents when given long term or expose the patient to increased
risk.
Potential pharmacological interventions for
preventing or treating SVD
Supplement Table S1 highlights the potential mechanisms by
which multimodal drugs might work in patients with SVD,
including details of potential mechanisms for which there is
current evidence and relevant references. Note that many drugs
have little lacunar-specific data but where available this is high-
lighted. A list of relevant completed trials where either patients
with SVD were included, or where SVD was an outcome, is given
in Supplement Table S2. Relevant systematic reviews of drugs that
may be of value in SVD are listed in Supplement Table S3. Supple-
ment Table S4 lists ongoing trials.
Acetylcholinesterase inhibitors and other
anti-dementia drugs
Anti-cholinesterase inhibitors (AChEI) prevent the breakdown of
acetylcholine, a neurotransmitter, by acetylcholinesterase. Four
drugs are licensed for treating mild-to-moderate Alzheimer’s
Disease: tacrine, rivastigmine, galantamine and donepezil; a fifth
licensed drug, memantine, is a non-competitive NMDA receptor
antagonist. Short-term trials of these drugs in vascular cognitive
impairment and vascular dementia have given mixed results but
small effects have been reported for donepezil, memantine and
galantamine (Supplement Table S3).Although some patients with
SVD will, inevitably, have been included in these trials, the pro-
portion is unclear. No relevant data were found for rivastigmine
(Supplement Table S3).
The relevance of AChEI to the prevention or treatment of SVD
is probably limited (see mechanisms listed in Supplemental
Table S1): existing trials were short-term (6 months) treatment
Fig. 1 Venn diagram showing relationship between small vessel disease and other forms of stroke. The embedded neuroimages show, clockwise from the
top: intracerebral haemorrhage (ICH), microbleeds, lacunes (‘lakes’ of cerebrospinal fluid), white matter hyperintensities (WMH), and an acute lacunar
infarct (LACI). Percentages relate to SVD etiologies and complications and are approximate: ‘?’ indicates a lack of data.
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rather than prevention studies, the observed effect on cognition
assessed using the Alzheimer’s Disease Assessment Scale (ADAS-
Cog) was small (Supplement Table S2) and of questionable clini-
cal relevance (ADAS-Cog ≥ 4 is considered worthwhile (19)),
benefit on the ADAS-Cog is of limited relevance to VaD since it
does not adequately measure executive function (the Vascular
Dementia Assessment Scale, VaDAS, addresses this deficiency but
relevant data for AChEI are not available), and the drugs are not
disease-modifying for Alzheimer’s Disease (and similarly are
unlikely to be post-lacunar stroke).
Anticoagulation
Atrial fibrillation (AF) is a major risk factor for both stroke, and
for cognitive decline and dementia. Although antiplatelets are
ineffective for preventing stroke in patients with AF, warfarin (an
antagonist of vitamin K1 recycling) reduced recurrence by two-
thirds in the ‘European Atrial Fibrillation Trial’ (Supplement
Table S2). In view of the need for regular monitoring and numer-
ous drug and food interactions, novel fixed dose anticoagulants
have been developed (apixaban, dabigatran, rivaroxaban) and
these are as effective (and potentially more effective) than warfa-
rin at preventing stroke, and recurrent stroke (subtype unspeci-
fied), in patients with AF (Supplement Table S2). Although
cardioembolism is an infrequent cause of lacunar ischemic stroke
(20), patients with cardioembolic sources who present with
lacunar ischemic stroke should have secondary prevention treat-
ment as any other cardioembolic stroke. Apixaban is also more
effective than aspirin in AF. Unfortunately, none of these modern
trials reported results for outcomes in the subgroup of patients
with SVD, or on the effect of treatment on cognition or SVD as an
outcome.
In view of the beneficial effect of oral anticoagulation in AF,
warfarin has also been tested in patients with prior stroke (includ-
ing some with a small subcortical infarct) who are in sinus
rhythm. With conventional anticoagulation (INR 2–3), warfarin
was not superior to aspirin (Supplement Table S2). In the SPIRIT
trial, high dose warfarin (INR 3.0–4.5) was associated, as com-
pared with aspirin, with increased intracerebral haemorrhage,
particularly in patients with manyWMH (Supplement Table S2).
Anti-inflammatory agents
Steroids and non-steroidal anti-inflammatory drugs (NSAIDs)
are the two archetypal classes of anti-inflammatory agents; ste-
roids are not further discussed here since long-term use would
probably cause more problems (e.g. hypertension, hyperglycemia,
osteoporosis) than they might solve by attenuating SVD. NSAIDs
such as aspirin, ibuprofen and naproxen inhibit the formation of
inflammatory-causing prostaglandins through inhibiting the
activity of cyclooxygenase-2 (COX2, Supplement Table S1), as
well as inhibiting COX1 which leads to gastrointestinal bleeding.
Selective COX2-inhibitors (coxibs) are not relevant here since
they increase vascular events in at-risk individuals.
Many other drugs classes have anti-inflammatory effects mani-
fest as reductions in the activity of the cellular components of
inflammation (white cell activation, typically neutrophils and
monocytes, and white cell-platelet conjugates), and/or soluble
biomarkers (such as CRP, cytokines and interleukins). Example
agents include nitric oxide (NO) donors, prostacyclin (PGI2),
phosphodiesterase (PDE)-inhibitors, and statins (as discussed
below and in Supplement Table S1).
Antiplatelet agents
Commonly used oral antiplatelet agents after stroke include
aspirin (typically 50 mg to 81 mg daily), cilostazol, clopidogrel,
dipyridamole, and triflusal. Practically, aspirin and clopidogrel
can be considered to have moderately potent antiplatelet effects,
and cilostazol, dipyridamole and triflusal to have mild antiplatelet
activity; very potent oral antiplatelet agents such as lotrafiban, a
glycoprotein IIb/IIIa antagonist, are not used because of an
increased risk of death and bleeding (21). Although clopidogrel is
selective as an antiplatelet agent, the other drugs have extra-
platelet effects, including reducing endothelial cell dysfunction,
and white cell and smooth muscle cell activity (Supplement
Table S1, Fig. S2). All have RCT data to support their efficacy in
preventing recurrence after any ischemic stroke (and TIA, for
some) (Supplement Table S3). In most of the above trials, differ-
entiation of patients with lacunar stroke from other subtypes was
not done, or the results were not reported separately.
The combination of two antiplatelet drugs vs. mono antiplate-
let therapy has also been studied although the data vary between
acute and chronic administration after stroke. In acute stroke,
short-term dual therapy is superior to mono therapy such that the
reduction in early stroke recurrence exceeds any increase in major
bleeding, as seen in both a meta-analysis and subsequent indi-
vidual trial (Supplement Tables S2 and 3). However, the picture is
mixed for chronic administration after stroke; whilst the combi-
nation of aspirin and dipyridamole is superior to either agent
alone (Supplement Table S3), combined aspirin and clopidogrel
are not superior to monotherapy since excess bleeding risk
matches or outweighs any reduction in recurrence (Supplement
Table S2) (22), particularly in patients with lacunar stroke (Bath
P, European Stroke Conference, May 2012).
Across a wider and mixed group of 90 934 patients with isch-
emic heart disease or stroke (either receiving short- or long-term
treatment), the adverse risk-benefit ratio of combined aspirin and
clopidogrel vs. aspirin was confirmed in a meta-analysis of RCTs
except in lacunar stroke where any reduction in MI with dual
antiplatelet therapy was offset by an increase in haemorrhage and
death (23). Only one completed trial has tested chronic triple
antiplatelet therapy (aspirin, clopidogrel and dipyridamole) and
this was stopped early because the comparator, aspirin alone, was
considered unethical to give beyond 2006 (Supplement Table S2);
nevertheless, in this small population of patients, mostly with
lacunar stroke (71%), chronic triple antiplatelet therapy was asso-
ciated with increased bleeding.
Importantly, all the above trials recruited a mixed group of
patients including both lacunar and non-lacunar stroke and most
did not characterize patients at baseline as one or the other. Only
one RCT, the ‘Secondary Prevention of Small Subcortical Stroke’
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(SPS3) study (Supplement Table S2), has tested antiplatelet drugs
specifically in patients with lacunar stroke. (SPS also assessed
intensity of blood pressure lowering in a factorial design [Supple-
ment Table S2].) SPS3 compared long-term therapy with com-
bined aspirin and clopidogrel vs. aspirin alone in 3020 patients
with MRI DWI-proven lacunar stroke; dual therapy caused excess
haemorrhage and death and the trial was stopped prematurely.
Since patients with lacunar stroke would be expected to have less
atheroma (5) it is perhaps unsurprising, in retrospect, that isch-
emic vascular events were unchanged in the face of an increase in
bleeding. A similar increase in haemorrhage was also seen in the
subgroup of patients with prior stroke (47% with SVD) random-
ized to vorapaxar vs. placebo in the TRA-2P trial, where vorapaxar
was given on top of existing antiplatelet therapy, i.e. amounting to
dual therapy (24). The small subgroup in whom lacunar ischemic
stroke occurs above a carotid atheromatous stenosis (20), or who
have intracranial large artery or branch artery atheroma might be
expected to benefit from antiplatelet drugs although such patients
must have been included in SPS3 (which did not show benefit)
and it is difficult to distinguish atheromatous from intrinsic small
vessel lacunar ischemic stroke at present. The lack of benefit of
antiplatelet agents in lacunar stroke in trials is supported by labo-
ratory studies where particulate hemostasis, i. e. that based on
platelets, is not abnormal in SVD (25,26). The effects of antiplate-
lets on the other types of SVD – WMH, lacunes, micro-bleeds –
have not been studied in detail.
Blood brain barrier (BBB) modulation
BBB function is damaged by metabolic derangement such as
hyperglycemia and hypoxia, as seen experimentally in culture
systems (27–29). Increased BBB permeability occurs with normal
ageing (30) and is accelerated in WMH and lacunar stroke (3).
However, there is little evidence on interventions that might
tighten the BBB thereby reducing the transit of potentially toxic
factors through the vessel wall and into parenchymal tissue. Anti-
oxidants and VEGF antibodies strengthen the BBB in experimen-
tal studies (Supplement Table S1). Of more practical use is the
observation that both cGMP (dipyridamole) and cAMP (cilosta-
zol, pentoxifylline) modulators can improve BBB integrity, at least
in experimental studies (Supplement Table S1). Other com-
pounds of potential interest include fasudil and topiramate
(Supplement Table S1).
Blood pressure (BP) lowering
Hypertension is the most important modifiable risk factor for
stroke and is also the strongest known vascular risk factor for
SVD.Multiple trials have shown that treating high BP reduces first
stroke. Only one trial assessed the effect of BP lowering on the
type of any resulting stroke; in SHEP, antihypertensive therapy
(chlorthalidone, with or without atenolol or reserpine) reduced
the incidence of ischemic stroke, including lacunar subtype
(Supplement Table S2).
A few trials have investigated secondary prevention after stroke
either testing the treatment of hypertension, or of lowering BP
irrespective of starting level; these found that antihypertensive
drugs reduce second stroke (Supplement Table S3). With one
exception, the studies either did not phenotype the type of index
stroke, or did not report these results in stroke subtypes.
The SPS3 trial compared intensive vs. guideline BP lowering
and found no significant reduction in recurrent stroke (Supple-
ment Table S2); however, there was a strong trend to reduced
recurrence and meta-analysis of this and other data in SVDmight
well show a significant effect. In the absence of other data on
lacunar stroke, data on other SVD features are relevant. Although
antihypertensive therapy may be associated with less WMH pro-
gression in observational studies, little (PROGRESS, n = 192) or
no (PRoFESS, n = 771) effect on WMH progression was seen in
substudies of RCTs (Supplement Table S2). SPS3 found no benefit
for intensive versus guideline BP lowering on long-term cognition
after lacunar stroke (31).
Unlike antiplatelet therapy, where just two years of therapy can
be enough to demonstrate a therapeutic effect on outcome, anti-
hypertensive agent trials may need longer treatment and
follow-up periods to detect reductions in stroke or SVD. In
general, post-stroke BP trials can be criticized for starting treat-
ment too late after ictus, not continuing treatment for long
enough, and not obtaining a large enough separation in BP
between treatment and control groups. Nevertheless, lowering BP
too much might also be hazardous, the so-called ‘J-shaped’ curve,
especially in older patients or in those with a prior stroke (32,33).
Blood pressure is but one hemodynamic measure altered by
antihypertensive drugs and other parameters are also related to
stroke, cognition and disability; these include heart rate (34), peak
BP and variability (35), and rate-pressure product. Furthermore,
different antihypertensive drug classes are thought to have differ-
ential effects on stroke and cardiovascular disease prevention
(Supplement Table S3), but there is no information on differential
effects of classes in different stroke subtypes.
Endothelin
Endothelin-1 is a potent peptide vasoconstrictor released by
endothelial cells that acts as the physiological antagonist of NO
(and PGI2). Most research has focused on the potential treatment
of systemic and pulmonary hypertension with endothelin recep-
tor antagonists. But endothelin may contribute to vasospasm
associated with subarachnoid haemorrhage (SAH), and has been
used to induce experimental ischemic stroke (36,37). Although
endothelin receptor antagonists (such as clazosentan and TAK-
044) have been used for the treatment of SAH, their use in SVD
has not been reported.
Immunosuppressive agents
The inflammatory nature of SVD suggests that immunomodula-
tory agents might also have a role in preventing or delaying the
progression of SVD. Potent small molecules (e.g. methotrexate)
and monoclonal antibodies (e.g. anti TNF-alpha) probably have
no role in view of their known toxicity and carcinogenic profile,
although at least one trial is soon to start testing methotrexate in
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acute myocardial infarction (http://clinicaltrials.gov/show/
NCT01741558); additionally, monoclonal antibodies are very
expensive and usually have poor brain penetration when given
systemically. But less toxic and expensive agents might be relevant
such as thalidomide, a teratogen, currently used in older people in
the management of myeloma. Although its mechanisms of action
are incompletely elucidated, thalidomide inhibits TNF-α and is
antiangiogenic. Changes in the immune response with advancing
age would be a consideration if such agents were to be used in
SVD.
Lipid lowering
The main therapeutic and licensed role for statins (HMG-CoA
reductase inhibitors) is to lower LDL-cholesterol in patients with
a high risk of developing large artery atheromatous disease (MI or
stroke), or who already have it. In addition to lipid lowering,
statins exhibit multiple other effects (pleiotropism) including
antiplatelet, anti-inflammatory and pro-endothelial activity
(Supplement Table S1). These effects are mediated, in part, by
increased vascular NO production through activation of nitric
oxide synthase-3 (NOS, endothelial NOS, eNOS). Statins may be
categorized by:
Productionmethod – fermentation-derived (pravastatin, simv-
astatin) or synthetic (atorvastatin, fluvastatin, rosuvastatin).
Potency in LDL-lowering at maximum dose – rosuvasta-
tin > atorvastatin > simvastatin > pravastatin > fluvastatin.
Solubility – hydrophilic: fluvastatin, pravastatin, rosuvastatin;
lipophilic: atorvastatin, simvastatin.
Such pharmacological differences and pleiotropic behaviour
may impact on their ability to modulate the development or
extension of SVD.
Statins reduce both first and recurrent stroke (Supplement
Table S3). Although there are no large trials specifically after
lacunar stroke, atorvastatin reduced recurrent stroke by similar
amounts in small vessel (n = 1409) and large artery stroke (hazard
ratio 0.85, 0.70 respectively) in the SPARCL trial (Supplement
Table S2). In contrast, neutral effects were seen for simvastatin on
amelioration of cognitive decline in the HPS mega-trial, for
pravastatin on WMH progression in 535 patients in PROSPER,
for simvastatin (20 mg daily for 24 months) on WMH progres-
sion in 208 patients in ROCAS; and atorvastatin (80 mg daily for
3 months) on cerebral vasoreactivity and endothelial function in
94 patients with recent lacunar stroke (Supplement Table S2).
Neurotrophins
Cerebrolysin is a peptide product derived from pig brain with
potential neurotrophic (including nerve growth factor activity)
and neuroprotective activity. The drug is administered as an intra-
venous preparation given daily for days or weeks. Small studies
have suggested that cerebrolysin might be effective in VaD
(Supplement Table S3) but further trials are needed and specific
effects in SVD have not been published. The relevance of cere-
brolysin to SVD prevention or treatment is unclear in view of the
need for intravenous administration (although a nasal prepara-
tion is in development).
Nitric oxide/cyclic GMP system
Nitric oxide is a key autocrine and paracrine mediator in numer-
ous physiological and pathophysiological processes. NO is syn-
thesized from the amino acid, L-arginine, by NO synthase
(including NOS-3/eNOS), and from nitrate then nitrite through
reduction. It stimulates down-stream processes through the
second messenger cyclic guanylate monophosphate (cGMP,
Supplement Table S1, Fig. S2). cGMP is broken down by phos-
phodiesterase, predominantly type 5. So, the vascular L-arginine/
NO/cGMP/PDE system may be up-regulated through enhancing
L-arginine or nitrate levels, increasing NO synthase activity,
administering NO donors, and blocking PDE activity. In respect
of actions that might be relevant to the development of SVD, NO
has antiplatelet, anti-leucocyte, anti-smooth muscle cell, and
other anti-inflammatory activity, as well as pro-endothelial and
blood-brain barrier actions (Supplement Table S1).
Increasing endogenous NO synthesis
Endogenous vascular NO synthesis may be augmented through
increasing blood substrate levels of L-arginine or nitrate, e.g.
through diet, detected as changes in systemic and cerebral hemo-
dynamics in some (38–40) but not all studies (41). The activity of
NOS-3 is up-regulated by statins (Supplement Table S1).
NO donors
In experimental studies, NO donors are neuroprotective (Supple-
ment Table S3) and anti-inflammatory, e.g. through inhibiting
white cell function (such as chemotaxis and adhesion, Supple-
ment Table S1). In stroke, NO donors lower blood pressure and
vasodilate cerebral vasculature (Supplement Table S2). It is
important to note that NO donors vary in their antiplatelet activ-
ity – those that inhibit platelets (NO itself, and donors that spon-
taneously release NO such as sodium nitroprusside) and those
that do not (organic nitrates such as isosorbide mononitrate and
glyceryl trinitrate). The absence in platelets of the metabolic
apparatus to release NO from organic nitrates explains this dif-
ference. Whether this explanation would be relevant in SVD-
prevention is not clear. Circulating NO levels are low in acute, and
probably chronic, stroke (42,43) although levels in lacunar stroke
have not been individually reported; hence, one action of NO
donors is to augment endogenous vascular NO levels.
cGMP augmentation/PDE5 inhibition
Phosphodiesterases (PDE) catalyze the hydrolysis of cyclic
nucleotides (cAMP, cGMP) to inactive 5’-cyclic nucleotides (44).
11 classes of PDEs (comprising more than 60 different isoforms)
exist with differential effects on cAMP and cGMP. PDE types
3 (PDE3, primarily of relevance to cAMP metabolism) and 5
(PDE5, cGMP), and their inhibitors, are of most relevance to
the vasculature and management post-stroke. Relevant PDE-
inhibitors are either non-selective (e.g. methylxanthines such
as caffeine, pentoxifylline and theophylline) or selective, e.g.
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cilostazol inhibits PDE3, dipyridamole inhibits PDE5 (Supple-
ment Table S1). Several PDE-inhibitors also exhibit adenosine
modulating effects acting either as adenosine re-uptake inhibitors
(cilostazol, dipyridamole, pentoxifylline) or as adenosine receptor
antagonists.
PDE5 inhibitors mimic many of the features of NO, including
exhibiting mild antiplatelet activity, and endothelial protection
(manifest as a reduction in von Willebrand factor) (Supplement
Table S1). The main PDE5-inhibitor of clinical relevance to stroke
is dipyridamole.
Dipyridamole is licensed for the secondary prevention of stroke
based on trials involving monotherapy or when given with aspirin
(Supplement Table S3). Although dipyridamole can cause a
NO-like headache, the presence of headache (indicating the pres-
ence of cerebrovascular reactivity) is associated with a reduced
rate of stroke recurrence (45).
Peroxisome proliferator-activated receptor
(PPAR)-gamma agonists
Pioglitazone, a PPAR-gamma inhibitor that is licensed for diabe-
tes management, has multiple properties that might attenuate
SVD, including BP modulation, pro-endothelial activity, anti-
vascular inflammation, lipid modulation, anti-smooth muscle
cell proliferation, and anti- fibrinolysis (Supplement Table S1).
However, treatment with pioglitazone is associated with a number
of adverse events such as weight gain, heart failure, and possibly
bladder cancer.
In a post hoc analysis, pioglitazone was observed to reduce
recurrence and major adverse cardiovascular events (MACE) in
984 patients with type II diabetes and previous stroke in the
PROactive trial; however the proportion of patients with SVDwas
not recorded at baseline (Supplement Table S2). Further, piogli-
tazone did not prevent first stroke.
Prostacyclin/cyclic AMP system
Prostacyclin I2 (PGI2), related prostaglandins (e.g. PGE2), and
their mimics, exert many of the effects seen with NO and cGMP
modifying agents (Supplement Table S1). This includes antiplate-
let, anti-smooth muscle and anti-inflammatory activity, and pro-
endothelial effects. PGI2 is synthesized from prostaglandin H2 by
prostacyclin synthase. Since PGH2 is synthesized by COX1/2
(PGH2 synthase), PGI2 production is attenuated by aspirin. Many
of the effects of PGI2 are mediated by the secondmessenger, cyclic
adenosine monophosphate (cAMP, Fig. 2), which is broken down
by PDE3 (among other PDEs).
Prostacyclin and mimetics
Intravenous PGI2 has been assessed in several small trials in
acute stroke (Supplement Table S3). In the context of SVD
prevention/treatment, PGI2 and its prostaglandin derivatives and
mimetics (e.g. beraprost, treprostinil), are probably not suitable
agents since they have to be given intravenously or very fre-
quently by inhalation, and no suitable oral preparations are
available.
Fig. 2 Targets and potential pharmacological interventions for preventing and/or treating small vessel disease. The green arrows indicate the site of some
actions of a drug. The diagram indicates drugs acting on red blood cells, platelets, endothelial cells, smooth muscle cells (and potentially on pericytes).
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cAMP augmentation/PDE3 inhibition
The PGI2/cAMP system may best be stimulated chronically by
reducing the metabolism of cAMP with an oral PDE3 inhibitor
such as cilostazol, pentoxifylline or triflusal. PDE-inhibitors have
the added advantage that they may increase NO production by
modulating dimethylarginine dimethylaminohydrolases (Supple-
ment Table S1).
Cilostazol: Cilostazol is licensed for peripheral vascular disease
(PVD) (46) but has also been shown to reduce recurrent ischemic
stroke, with fewer haemorrhagic complications than aspirin
(Supplement Tables S2–S4). Cilostazol was also assessed in
chronic lacunar stroke for effects on forearm vascular reactivity
(47), and acute lenticulostriate stroke for neurological deteriora-
tion (48). Experimentally, cilostazol may enhance white matter
regeneration after ischemia (Supplement Table S2) (49); in
SHRSP, it both improved motor and cognitive function and
reduced infarct size as compared with aspirin (50). Further trials
of cilostazol beyond those listed in Supplementary Table S4 are
thought to be ongoing.
Pentoxifylline: Pentoxifylline, propentofylline and pentifyline
are related methylxanthines that have been studied in several
trials in acute ischemic stroke and dementia prevention (Supple-
ment Table S3); although some results were promising, the RCTs
were small and of suboptimal design. Pentoxifylline is licensed for
the treatment of PVD and improves the healing of venous leg
ulcers. Theophylline, another methylxanthine (and commonly
found in tea), has similar effects.
Triflusal has multiple modes of action including acting as an
inhibitor of COX1 (in platelets but not endothelium) and PDE3,
protecting PGI2 from metabolism, and promoting the release of
NO (through stimulating NOS-3) from white cells. Triflusal is
licensed for the prevention of recurrent vascular events in high-
risk individuals.
None of the larger stroke trials of PDE-inhibitors have focused
on patients with SVD; indeed stroke subtype was usually not
phenotyped so the beneficial resultsmight bemore or less relevant
for patients with SVD as compared with other types of stroke.
Rho-kinase (ROCK)-antagonists
Fasudil, a selective rho-kinase inhibitor, increases the integrity of
the blood brain barrier and reduces small muscle cell prolifera-
tion (Supplement Table S1) in acute experimental models of
stroke. It improved early neurological deficit vs. placebo in 160
patients with acute ischemic stroke; the subtype of stroke was not
specified in this study (51) and there are no specific data for SVD.
The effects on chronic BBB dysfunction, which might have a
different mechanism to that seen after acute ischemic stroke, are
not known.
Stimulants
Stimulant agents include sympathomimetics (e.g. amphetamine)
and eugeroics (which increase catecholaminergic and histamin-
ergic activity in the brain). Modafinil, an eugeroic that inhibits
dopamine transport, is licensed for the treatment of narcolepsy,
and potentially enhances cognition and reduces fatigue. However,
its role in stroke and SVD remains untested. Although amphet-
amine has been assessed for promoting recovery after stroke, it
increased BP and was associated with increased deaths (Supple-
ment Table S3).
Vitamins
Amongst multiple classes of vitamins, the ones potentially of
most interest to stroke are those that modulate homocysteine
metabolism, namely B6, B12 and folate. Although trials of these
failed to prevent stroke recurrence (Supplement Table S3), a small
neuroimaging substudy (using MRI) from the large VITATOPS
trial suggested that B vitamins might be associated with less
WMH change in patients with severe WMH at baseline (Supple-
ment Table S2).
Xanthine oxidase inhibitors
Allopurinol and febuxostat, xanthine oxidase inhibitors, lower
plasma uric acid levels and are licensed for the prevention of gout
(Supplement Table S3). Allopurinol also increases NO availabil-
ity, has anti-inflammatory effects, reduces augmentation index
(reducing stiffness in large compliance arteries), reduces left
ventricular hypertrophy, and modulates BP. However, the type,
magnitude and direction of the relationship between urate
and vascular disease is unclear, and might be explained by
co-association with body mass index (52). The effects of allopuri-
nol in clinical trials are mixed, and allopurinol is associated with
adverse events at high dose. In a small study in 50 patients with
subcortical stroke, allopurinol did not alter cerebral vasoreactiv-
ity, augmentation index or soluble markers of inflammation
(Supplement Table S2).
Other potential therapeutic strategies
Multiple other interventions may have properties that are relevant
to SVD-prevention:
Information from experimental stroke models: Several other
interventions have been proposed as treatment or prevention
strategies for SVD, including nicotiflorin (a flavonoid), minocy-
cline and relaxin (Supplement Table S3). However many of the
experimental models were not relevant to human intrinsic SVD
and the evidence for any of these drugs is limited by small
numbers and suboptimal methods.
Lifestyle modifications (53): These include smoking cessation,
salt reduction, increased dietary nitrates, dietary flavonones (54),
a healthy diet (55), and exercise (56). However, whether any of
these have differential effects on lacunar stroke/SVD or are simply
good for general health is unclear. Clearly smoking cessation is a
major public health target worldwide and should be encouraged.
Decreasing salt intake reduces blood pressure, platelet adhesion
and oxidative stress and improves vascular function in salt-replete
and sensitive individuals (57,58) so probably benefits both large
artery disease and SVD. Short-term dietary nitrates increase
frontal white matter perfusion (40) and increase cerebrovascular
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reactivity in young people (59). L-arginine supplements (e.g. in
the form of ‘Heart bars’) reduce eclampsia (60). Some trials are
testing multiple risk factor interventions, i.e. two or more of the
above (61). A recent systematic review identified 25 non-
pharmacological and eight multiple risk factor intervention trials;
of these, 16 were published and 17 ongoing (Supplement
Tables S3 and S4); these trials are not discussed further here.
It is worth noting that lifestyle modifications can be difficult to
implement, and are very difficult to sustain chronically in a trial
environment.
Cognitive interventions: Several ongoing trials are assessing a
variety of cognitive interventions, including coaching, strategy
training, and reading skills. Such trials are not discussed further
here.
Preventing and treating SVD
Existing data
Ultimately, new large scale RCTs will be needed to assess whether
specific interventions can prevent the development of SVD
and/or treat its progression. But information is required now on
whether current guideline-based treatments (e.g. antihyperten-
sives, antiplatelets and statins) have any benefit for preventing
first or recurrent lacunar stroke; much might be learnt from
existing trials of these interventions, especially where patients
with identified SVD were randomized (e.g. with lacunar stroke
as in SPS3 (22,62)), or where SVD outcomes were recorded
(such as WMH, as assessed in a PRoFESS substudy, Supplement
Table S2).
To this end, the authors are coordinating a data-pooling project
with the aim of collecting individual patient data on clinical and
neuroimaging measures from appropriate RCTs. The aim is to
assess whether existing pharmacological interventions already
have evidence for preventing SVD development and progression.
Nevertheless, this approach will be limited since most trials did
not accurately-phenotype the diagnosis or outcome of SVD;
further, even where subtyping was attempted, the imperfect dis-
tinction of lacunar from non-lacunar stroke based on clinical
syndrome plus CT scanning (as used in most previous trials) will
have misclassified about 20% of lacunar as non-lacunar strokes
and vice versa (63), thus adding ‘noise’ to any retrospective
analysis.
Ongoing and planned RCTs
A number of ongoing trials are assessing patients with SVD, as
described in Supplement Table S4. These may be categorized
according to their design:
Aim: Prevention of new events, or treatment of existing disease.
Patients: SVD absent or present, pre- or post-stroke, cognition
normal or impaired.
Intervention: Drug, device, or management strategy (intensity
of treatment).
Comparator: Placebo, or open-label.
Outcome: Prevention of SVD or stroke, functional outcome,
cognition or neuroimaging measure.
Design: Double-blind placebo-controlled, single-blind
blinded-outcome, or open-label blinded-outcome.
Which interventions should be tested for SVD?
This review has highlighted potential mechanisms that might
modulate SVD and several drugs with one or more of these rel-
evant mechanisms of action. However, as yet none of these inter-
ventions have been shown definitely to prevent or treat SVD.
Nevertheless, some provisional conclusions can be drawn:
1. Both BP and lipid lowering are standard secondary prevention
interventions after an ischemic stroke or TIA. Similarly, both have
biologically plausible mechanisms by which they might prevent
SVD. But their routine use means that further testing would
necessitate a comparison either of intensive vs. standard (guide-
line) lowering, or a comparison of drug classes (as discussed
above).
2. Potent antiplatelet agents (aspirin, clopidogrel) do not appear
to have a role since they are already used routinely, either indi-
vidually or together, after ischemic stroke whilst long-term inten-
sive treatment based on their combination is associated with
increased major intra- and extra-cranial bleeding (Supplement
Tables S2 and 3).
3. Agents that increase cAMP or cGMP appear promising with
theoretical protective effects on endothelium and the blood-brain
barrier, and attenuating effects on inflammation, platelets,
smooth muscle cell and white cells. Hence drugs that induce
cAMP or reduce its degradation (PDE3 inhibitors such as amino-
phylline, cilostazol, pentoxifylline or triflusal), or induce cGMP
(NO donors) or reduce its degradation (PDE5 inhibitors such as
dipyridamole) are candidates for testing, especially since all are
already licensed for clinical use. One concern is that the mild
anti-platelet effects of PDE inhibitors (e.g. cilostazol, dipyrida-
mole) and their chronic co-administration with a potent anti-
platelet agent (such as clopidogrel) might increase bleeding,
although this was not seen when aspirin and dipyridamole were
used together in ESPS-2 and ESPRIT (Supplement Table S2).
4. To maximize modulation of the multiple systems that contrib-
ute to the development and extension of SVD, it may be necessary
to use either drugs that have multiple mechanisms of action (such
as NO donors, PDE-inhibitors and statins, Supplement Table S1),
or combinations of drugs, or a mix of both.
5. Potential combinations of drugs are either:
a. Those that have unrelated but potentially synergistic effects.
Useful combinations might include assessing two or more of
the various types of interventions described above, e.g. inten-
sive BP lowering and statins, PPAR-gamma antagonist and
xanthine oxidase inhibitor, or intensive BP lowering and
raising NO.
b. Combining agents that have related effects, e.g. by raising
cAMP and cGMP. Potential combinations include dipyrida-
mole and pentoxifylline (64), dipyridamole and cilostazol
(65), and isosorbide mononitrate and cilostazol. Alternatively,
hybrid drugs that comprise a NO donor and cAMPmodulator
might be relevant, e.g. cilostazol dinitrate (66).
6. It is conceivable that some treatment strategies might have
differential effects on the various types of SVD;whilst BP lowering
might be beneficial on all, statins and antiplatelets might be ben-
eficial in reducing lacunar stroke but increase symptomatic bleed-
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ing from micro-bleeds due to their antithrombotic activity. This
emphasizes the need tomonitor all features of SVD in future trials.
Conclusions
There are no established therapeutic strategies for either prevent-
ing or treating SVD althoughmore information about strategies to
avoid and that show promise are emerging (4). A number of
routine vascular prophylaxis strategies, especially lowering BP,
might reduce SVD but their current guideline use means any
future trials would have to test intensity of treatment. Other
potential interventions are not in routine use post stroke and have
multiple activities with the potential for targeting mechanisms of
SVD formation. It is clear that further trials dedicated to prevent-
ing the development or worsening of SVD are now required.
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